University of Hull logo

Urine biomarkers for the early detection of ovarian cancer – are we there yet? (2019)
Journal Article
Grayson, K., Gregory, E., Khan, G., & Guinn, B. (2019). Urine biomarkers for the early detection of ovarian cancer – are we there yet?. Biomarkers in Cancer, 11, https://doi.org/10.1177/1179299x19830977

Ovarian cancer affects around 7500 women in the United Kingdom every year. Despite this, there is no effective screening strategy or standard treatment for ovarian cancer. If diagnosed during stage I, ovarian cancer has a 90% 5-year survival rate; ho... Read More

Antigenic targets for the immunotherapy of acute myeloid leukaemia (2019)
Journal Article
Khan, G., Orchard, K., & Guinn, B. (2019). Antigenic targets for the immunotherapy of acute myeloid leukaemia. Journal of Clinical Medicine, 8(2), 134. https://doi.org/10.3390/jcm8020134

One of the most promising approaches to preventing relapse is the stimulation of the body's own immune system to kill residual cancer cells after conventional therapy has destroyed the bulk of the tumour. In acute myeloid leukaemia (AML), the high fr... Read More

Application of the pMHC Array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis (2015)
Journal Article
Brooks, S. E., Bonney, S. A., Lee, C., Publicover, A., Khan, G., Smits, E. L., …Guinn, B. (2015). Application of the pMHC Array to characterise tumour antigen specific T cell populations in leukaemia patients at disease diagnosis. PloS one, 10(10), https://doi.org/10.1371/journal.pone.0140483

Immunotherapy treatments for cancer are becoming increasingly successful, however to further improve our understanding of the T-cell recognition involved in effective responses and to encourage moves towards the development of personalised treatments... Read More

Analogue peptides for the immunotherapy of human acute myeloid leukemia (2015)
Journal Article
Hofmann, S., Mead, A., Malinovskis, A., Hardwick, N. R., & Guinn, B. (2015). Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunology, Immunotherapy, 64(11), 1357-1367. https://doi.org/10.1007/s00262-015-1762-9

The use of peptide vaccines, enhanced by adjuvants, has shown some efficacy in clinical trials. However, responses are often short-lived and rarely induce notable memory responses. The reason is that self-antigens have already been presented to the i... Read More

A novel zinc finger gene,ZNF465, is inappropriately expressed in acute myeloid leukaemia cells: ZNF465 Expression in Acute Myeloid Leukaemia (2015)
Journal Article
Collin, J. F., Wells, J. W., Czepulkowski, B., Lyne, L., Duriez, P. J., Banham, A. H., …Guinn, B. (2015). A novel zinc finger gene,ZNF465, is inappropriately expressed in acute myeloid leukaemia cells: ZNF465 Expression in Acute Myeloid Leukaemia. Genes, Chromosomes and Cancer, 54(5), 288-302. https://doi.org/10.1002/gcc.22242

To increase our knowledge of leukaemia‐associated antigens, especially in acute myeloid leukaemia (AML) M4, we prepared a phage display cDNA library using mRNA from the bone marrow cells of a patient with AML M4 at diagnosis. We immunoscreened 106 pf... Read More

Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer (2015)
Journal Article
Khan, G., Brooks, S. E., Mills, K. I., & Guinn, B. (2015). Infrequent expression of the Cancer-Testis antigen, PASD1, in ovarian cancer. Biomarkers in Cancer, 7, 31–38. https://doi.org/10.4137/bic.s28378

Ovarian cancer is very treatable in the early stages of disease; however, it is usually detected in the later stages, at which time, treatment is no longer as effective. If discovered early (Stage I), there is a 90% chance of five-year survival. Ther... Read More

Oral tolerance to cancer can be abrogated by T regulatory cell inhibition (2014)
Journal Article
Whelan, M. C., Casey, G., Larkin, J. O., Guinn, B., O'Sullivan, G. C., & Tangney, M. (2014). Oral tolerance to cancer can be abrogated by T regulatory cell inhibition. PloS one, 9(5), https://doi.org/10.1371/journal.pone.0097602

Oral administration of tumour cells induces an immune hypo-responsiveness known as oral tolerance. We have previously shown that oral tolerance to a cancer is tumour antigen specific, non-cross-reactive and confers a tumour growth advantage. We inves... Read More

PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies (2013)
Journal Article
Khan, G., Denniss, F., Mills, K. I., Guinn, B., & Pulford, K. (2013). PASD1: A Promising Target for the Immunotherapy of Haematological Malignancies. Genetic Syndromes and Gene Therapy, 04(09), https://doi.org/10.4172/2157-7412.1000186

In general, there is a lack of good immunotherapy targets within the spectrum of haematological malignancies. However haematopoietic stem cell transplants and continuing antigen discovery have allowed further insight into how further improvements in... Read More